Matches in SemOpenAlex for { <https://semopenalex.org/work/W101320054> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W101320054 endingPage "7" @default.
- W101320054 startingPage "1171" @default.
- W101320054 abstract "Many patients with rheumatoid arthritis (RA) need continuous medication, bringing considerable costs for drugs and a need for monitoring adverse drug reactions. We studied drug exposure, drug costs, and adverse drug reactions in patients with RA in Sweden from 1987 to 1997.Prescription patterns, drug costs, and adverse drug reactions, and their distributions and trends were analyzed by cross sectional annual data. Drug exposures and costs were assessed from the National Diagnosis and Therapy Survey. All costs were recalculated to the 1997 level using the drug price index. Information on adverse drug reactions was obtained from the national pharmacovigilance system.The drug prescription level was, on average, 2 defined daily doses (DDD) throughout the study period. Nonsteroidal antiinflammatory drugs (NSAID) accounted for > 40% of the drugs prescribed, methotrexate (MTX) 10%, corticosteroids 10%, and sulfasalazine 5%. Analgesics and opioids made up 14% of prescriptions - a low estimate considering the availability of over-the-counter preparations. Disease modifying antirheumatic drugs (DMARD) increased their proportion from 28.5 to 39.3%. Total costs were stable at $16 million US annually. NSAID costs decreased, while those of sulfasalazine, MTX, and cyclosporine increased. On average, 91 adverse drug reactions were reported annually. Hematological reactions (agranulocytosis, thrombocytopenia, leukopenia, pancytopenia) predominated, constituting 21% of reported reactions. Skin and gastrointestinal reactions, mainly mild, accounted for 15 and 14%, respectively. Deaths from adverse drug reactions were uncommon, about 3 per year, and were mainly attributed to hematological reactions.The total volume as well as the total cost of drug consumption for RA in Sweden was relatively constant during our 11 year observation period, despite a notable increase in the use of DMARD. This was mainly due to a decrease in costs per DDD of NSAID, and an increased use of cyclosporine. Drug related adverse reactions were dominated by hematological reactions, and fatal events were few. This emphasizes the need for an extended evaluation of which safety procedures are most cost effective for monitoring the drugs used for RA." @default.
- W101320054 created "2016-06-24" @default.
- W101320054 creator A5053828409 @default.
- W101320054 creator A5080998055 @default.
- W101320054 creator A5083214196 @default.
- W101320054 creator A5088871148 @default.
- W101320054 date "2000-05-01" @default.
- W101320054 modified "2023-10-17" @default.
- W101320054 title "Rheumatoid arthritis in Sweden. Drug prescriptions, costs, and adverse drug reactions." @default.
- W101320054 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10813283" @default.
- W101320054 hasPublicationYear "2000" @default.
- W101320054 type Work @default.
- W101320054 sameAs 101320054 @default.
- W101320054 citedByCount "14" @default.
- W101320054 countsByYear W1013200542014 @default.
- W101320054 countsByYear W1013200542019 @default.
- W101320054 countsByYear W1013200542020 @default.
- W101320054 countsByYear W1013200542022 @default.
- W101320054 crossrefType "journal-article" @default.
- W101320054 hasAuthorship W101320054A5053828409 @default.
- W101320054 hasAuthorship W101320054A5080998055 @default.
- W101320054 hasAuthorship W101320054A5083214196 @default.
- W101320054 hasAuthorship W101320054A5088871148 @default.
- W101320054 hasConcept C126322002 @default.
- W101320054 hasConcept C197934379 @default.
- W101320054 hasConcept C2426938 @default.
- W101320054 hasConcept C2777575956 @default.
- W101320054 hasConcept C2779134260 @default.
- W101320054 hasConcept C2779383735 @default.
- W101320054 hasConcept C2780035454 @default.
- W101320054 hasConcept C2780479503 @default.
- W101320054 hasConcept C2780542314 @default.
- W101320054 hasConcept C2781059491 @default.
- W101320054 hasConcept C57658597 @default.
- W101320054 hasConcept C71924100 @default.
- W101320054 hasConcept C98274493 @default.
- W101320054 hasConceptScore W101320054C126322002 @default.
- W101320054 hasConceptScore W101320054C197934379 @default.
- W101320054 hasConceptScore W101320054C2426938 @default.
- W101320054 hasConceptScore W101320054C2777575956 @default.
- W101320054 hasConceptScore W101320054C2779134260 @default.
- W101320054 hasConceptScore W101320054C2779383735 @default.
- W101320054 hasConceptScore W101320054C2780035454 @default.
- W101320054 hasConceptScore W101320054C2780479503 @default.
- W101320054 hasConceptScore W101320054C2780542314 @default.
- W101320054 hasConceptScore W101320054C2781059491 @default.
- W101320054 hasConceptScore W101320054C57658597 @default.
- W101320054 hasConceptScore W101320054C71924100 @default.
- W101320054 hasConceptScore W101320054C98274493 @default.
- W101320054 hasIssue "5" @default.
- W101320054 hasLocation W1013200541 @default.
- W101320054 hasOpenAccess W101320054 @default.
- W101320054 hasPrimaryLocation W1013200541 @default.
- W101320054 hasRelatedWork W101320054 @default.
- W101320054 hasRelatedWork W1820622478 @default.
- W101320054 hasRelatedWork W2027887203 @default.
- W101320054 hasRelatedWork W2373186848 @default.
- W101320054 hasRelatedWork W2376918858 @default.
- W101320054 hasRelatedWork W2415558459 @default.
- W101320054 hasRelatedWork W2746133076 @default.
- W101320054 hasRelatedWork W2915905314 @default.
- W101320054 hasRelatedWork W3017376994 @default.
- W101320054 hasRelatedWork W3204285441 @default.
- W101320054 hasVolume "27" @default.
- W101320054 isParatext "false" @default.
- W101320054 isRetracted "false" @default.
- W101320054 magId "101320054" @default.
- W101320054 workType "article" @default.